Complementary, Bao et al. showed that rosiglitazone lowered BCAA levels following 6 months of therapy in T2DM patients [77], while Walford et al. [78] showed that BCAAs/AAAs decreased following glipizide treatment but increased in a metformin therapy group, with a stronger decrease in insulin sensitive than in insulin-resistant patients [79]. Here, INS is linked to type 2 diabetes mellitus.